Tema Heart & Health ETF HRTS
39.01 USD +0.53 (+1.38%)
Nov 9, 2026, 10:45 AM EST
39.01 Day range 39.01
32.59 52-week range 39.92
- YTD
- +10.54%
- 1 year
- +19.48%
News
benzinga.com From Shingles To Superbugs: Eli Lilly Expands Infectious Disease Push In Billion-Dollar Buying Wave Eli Lilly acquires Curevo, LimmaTech, and Vaccine Co. to expand its infectious disease portfolio and advance long-term disease prevention.
benzinga.com Why Is Eli Lilly Stock Gaining Today? Eli Lilly shares surged after FDA approval of its oral obesity drug Foundayo, boosting growth prospects in the weight-loss market.
benzinga.com 'Roche Restricts Consulting Work With Big Four Firms To Cut Costs' - Bloomberg https://www.bloomberg.com/news/articles/2026-03-24/roche-restricts-consulting-work-with-big-four-firms-to-cut-costs?utm_source=latest&utm_medium=share&utm_campaign=copy
benzinga.com Ultragenyx's Gene Therapy Study Shows Ammonia Reduction In Rare Metabolic Disorder Ultragenyx Phase 3 gene therapy data shows reduced ammonia levels in rare disease patients, with further results expected in 2027.
benzinga.com EXCLUSIVE: Weight-Loss Market Experts Scoop Up Novo Nordisk Stock After Worst Drop Since 2002 Following Drug Trial Miss Novo Nordisk's stock plunges 20% after underwhelming weight-loss trial results for its obesity drug. Analysts say market overreacted.
benzinga.com EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen' Novo Nordisk under political pressure over high U.S. drug prices as CEO testifies before Congress. PBMs and limited impact on company's bottom line.- benzinga.com EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players' Eli Lilly and Novo Nordisk face selloff as new weight-loss drugs threaten dominance. Shares of both companies drop significantly, highlighting need for diversification in this industry.
benzinga.com EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO The GLP-1 drug market for obesity treatment is expected to skyrocket to $1 trillion or more, according to Maurits Pot, founder and CEO of Tema ETFs.
benzinga.com Weight-Loss Drug Forecasts Skyrocket To $150B As Novo Nordisk, Eli Lilly Ramp Up Supply The global market for weight-loss drugs is expected to reach a staggering $150 billion by the early 2030s, a significant increase from the previous forecast of $100 billion. This surge is attributed…